At the recent 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago, Illinois, there were three presentations from the ABCD audit programme.
Dr Bob Ryder presented an ePoster and a poster from the ABCD EndoBarrier Worldwide Registry. His analysis was of data from 1298 patients from 37 centres in 12 countries. All had been treated with the Duodenal-Jejunal Bypass Liner (DJBL) also known as EndoBarrier® and RESET®. The analysis suggested that the considerable benefits of DJBL on weight, glycaemic control and cardiovascular risk factors outweigh the risks.
Dr Alex Liarakos presented a poster from the ABCD NHS England Nationwide Hybrid Closed-Loop (HCL) Pilot Audit. His analysis showed that HCL was associated with improvements in Diabetes-Related Distress in type 1 diabetes, irrespective of ethnicity, deprivation status, baseline glucose outcomes and hypoglycaemia awareness.
Dr Kyaw Linn Su Khin presented a poster in which she analysed data from both the ABCD Nationwide Semaglutide Audit and the ABCD Nationwide Oral Semaglutide Audit. Her aim was to compare the effectiveness of injectable vs. oral semaglutide. Her analysis showed that both oral and injectable semaglutide effectively reduce HbA1c levels in people with type 2 diabetes. Injectable semaglutide produced greater HbA1c reduction compared with oral. She concluded that the findings support personalized treatment choices based on individual needs.
